Molecular monitoring of minimal residual disease after non-myeloablative allografting for multiple myeloma

被引：0
|
作者：
Bruno, B
Ladetto, M
Mordini, N
Astolfi, M
Rotta, M
Cimolin, L
Compagno, M
Veneziano, L
Aitoro, G
Gallamini, A
Storb, R
Boccadoro, M
机构：
来源：
BONE MARROW TRANSPLANTATION | 2003年 / 31卷
关键词：
D O I：
暂无
中图分类号：
Q6 [生物物理学];
学科分类号：
071011 ;
摘要：
引用
收藏
页码：S123 / S124
页数：2
相关论文
共 50 条
  • [1] Prospective Molecular Monitoring of Minimal Residual Disease after Non-Myeloablative Allografting in Newly Diagnosed Multiple Myeloma
    Bruno, Benedetto
    Ferrero, Simone
    Drandi, Daniela
    Festuccia, Moreno
    Patriarca, Francesca
    Mordini, Nicola
    Cena, Silvia
    Barbero, Daniela
    Monitillo, Luigia
    Ferrando, Federica
    Brunello, Lucia
    Fanin, Renato
    Ghione, Paola
    Omede, Paola
    Giaccone, Luisa
    Palumbo, Antonio
    Passera, Roberto
    Boccadoro, Mario
    Ladetto, Marco
    BLOOD, 2014, 124 (21)
  • [2] Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma
    Ladetto, M.
    Ferrero, S.
    Drandi, D.
    Festuccia, M.
    Patriarca, F.
    Mordini, N.
    Cena, S.
    Benedetto, R.
    Guarona, G.
    Ferrando, F.
    Brunello, L.
    Ghione, P.
    Boccasavia, V.
    Fanin, R.
    Omede, P.
    Giaccone, L.
    Palumbo, A.
    Passera, R.
    Boccadoro, M.
    Bruno, B.
    LEUKEMIA, 2016, 30 (05) : 1211 - 1214
  • [3] Prospective molecular monitoring of minimal residual disease after non-myeloablative allografting in newly diagnosed multiple myeloma
    M Ladetto
    S Ferrero
    D Drandi
    M Festuccia
    F Patriarca
    N Mordini
    S Cena
    R Benedetto
    G Guarona
    F Ferrando
    L Brunello
    P Ghione
    V Boccasavia
    R Fanin
    P Omedè
    L Giaccone
    A Palumbo
    R Passera
    M Boccadoro
    B Bruno
    Leukemia, 2016, 30 : 1211 - 1214
  • [4] Molecular monitoring of chimerism and minimal residual disease in multiple myeloma patients after non-myeloablative stem cell transplantation
    Galimberti, S
    Benedetti, E
    Fazzi, R
    Papineschi, F
    Caracciolo, F
    Orciuolo, E
    Andreazzoli, F
    Morabito, F
    Cuzzola, M
    Martino, M
    Iacopino, P
    Petrini, M
    BONE MARROW TRANSPLANTATION, 2004, 33 : S112 - S112
  • [5] Qualitative and quantitative molecular follow up of minimal residual disease after non myeloablative allografting for multiple myeloma.
    Bruno, B
    Ladetto, M
    Astolfi, M
    Veneziano, L
    Cimolin, L
    Galletto, E
    Pagliano, G
    Rotta, M
    Mordini, N
    Giaccone, L
    Omedè, P
    Battaglio, S
    Storb, R
    Boccadoro, M
    BLOOD, 2004, 104 (11) : 366B - 366B
  • [6] Prognostic role of minimal residual disease in multiple myeloma patients after non-myeloablative allogeneic transplantation
    Galimberti, S
    Benedetti, E
    Morabito, F
    Papineschi, F
    Callea, V
    Fazzi, R
    Stelitano, C
    Andreazzoli, F
    Guerrini, F
    Ciabatti, E
    Martino, M
    Nobile, F
    Iacopino, P
    Petrini, M
    LEUKEMIA RESEARCH, 2005, 29 (08) : 961 - 966
  • [7] A non-myeloablative regimen with minimal non relapse mortality for allografting patients with Hodgkin's disease
    Kottaridis, P
    Milligan, D
    Chopra, R
    Craddock, C
    Mahendra, P
    Hunter, A
    Marsh, J
    Chakraverty, R
    Mills, A
    Kyriakou, C
    McKeag, N
    Hale, G
    Waldmann, H
    Linch, D
    Goldstone, A
    Mackinnon, S
    BONE MARROW TRANSPLANTATION, 2001, 27 : S66 - S66
  • [8] High rates of prolonged molecular remissions after tandem autologous non-myeloablative allografting in newly diagnosed myeloma
    Bruno, B.
    Ferrero, S.
    Drandi, D.
    Festuccia, M.
    Patriarca, F.
    Mordini, N.
    Cena, S.
    Barbero, D.
    Monitillo, L.
    Giaccone, L.
    Barbiero, S.
    Gallamini, A.
    Fanin, R.
    Passera, R.
    Palumbo, A.
    Boccadoro, M.
    Omede, P.
    Ladetto, M.
    BONE MARROW TRANSPLANTATION, 2013, 48 : S200 - S201
  • [9] Molecular remissions after non-myeloablative allografting for chronic myelocytic leukemia (CML).
    McSweeney, P
    Niederwieser, D
    Shizuru, J
    Radich, J
    Molina, A
    Hegenbart, U
    Chauncey, T
    Sandmaier, B
    Wolff, D
    Blume, K
    Storb, R
    BLOOD, 1999, 94 (10) : 710A - 710A
  • [10] Individual molecular monitoring of minimal residual disease after autotransplantation in patients with multiple myeloma
    Zherebtsova, V.
    Surin, V.
    Savchenko, V.
    Mendeleeva, L.
    Pokrovskaya, O.
    Turina, N.
    Misurin, A.
    BONE MARROW TRANSPLANTATION, 2007, 39 : S143 - S143
12345